SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
复制标题
DOI：
10.3389/fimmu.2020.569760
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Kalergis AM
中科院分区：
文献类型：
--
作者：
Canedo-Marroquín G;Saavedra F;Andrade CA;Berrios RV;Rodríguez-Guilarte L;Opazo MC;Riedel CA;Kalergis AM
世界卫生组织（WHO）在3月宣布了由严重急性呼吸系统综合征冠状病毒2（SARS-CoV-2）引起的大流行。这种新型传染病被命名为冠状病毒病19（COVID-19），截至2020年10月，全球已发现超过39，000，000例SARS-CoV-2病例，导致近1，100，000人死亡。在临床上，COVID-19的特点是临床表现，如发热、干咳、头痛，在更严重的情况下，会出现呼吸窘迫。此外，还描述了神经、心脏和肾脏相关症状。临床证据表明，免疫细胞迁移到受影响的器官可导致促炎介质的加速释放，促炎介质导致疾病，并使免疫反应成为COVID-19疾病发展过程中的主要参与者。由于目前的卫生状况，疫苗的开发势在必行。到目前为止，42种原型正在不同临床阶段的人体中进行测试，10种候选疫苗正在III期临床试验中进行评估。同样，寻求有效治疗最严重病例的努力也在不断取得进展。自COVID-19被描述以来，已经测试了几种潜在的治疗方法，包括抗病毒药物、抗寄生虫药物和免疫调节剂。最近，羟氯喹的临床试验一种很有前途的治疗药物被暂停。此外，美国食品和药物管理局（FDA）批准恢复期血清给药作为SARS-CoV-2患者的治疗。此外，单克隆抗体疗法也在开发中，以中和病毒并预防感染。在这篇文章中，我们描述了COVID-19疾病的临床表现和可用的免疫学信息。此外，我们还讨论了目前正在研究的治疗方法和预防这种疾病的疫苗的开发。
The World Health Organization (WHO) announced in March a pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). This new infectious disease was named Coronavirus Disease 19 (COVID-19), and at October 2020, more than 39,000,000 cases of SARS-CoV-2 have been detected worldwide leading to near 1,100,000 deaths. Clinically, COVID-19 is characterized by clinical manifestations, such as fever, dry cough, headache, and in more severe cases, respiratory distress. Moreover, neurological-, cardiac-, and renal-related symptoms have also been described. Clinical evidence suggests that migration of immune cells to the affected organs can produce an exacerbated release of proinflammatory mediators that contribute to disease and render the immune response as a major player during the development of the COVID-19 disease. Due to the current sanitary situation, the development of vaccines is imperative. Up to the date, 42 prototypes are being tested in humans in different clinical stages, with 10 vaccine candidates undergoing evaluation in phase III clinical trials. In the same way, the search for an effective treatment to approach the most severe cases is also in constant advancement. Several potential therapies have been tested since COVID-19 was described, including antivirals, antiparasitic and immune modulators. Recently, clinical trials with hydroxychloroquine—a promising drug in the beginning—were suspended. In addition, the Food and Drug Administration (FDA) approved convalescent serum administration as a treatment for SARS-CoV-2 patients. Moreover, monoclonal antibody therapy is also under development to neutralize the virus and prevent infection. In this article, we describe the clinical manifestations and the immunological information available about COVID-19 disease. Furthermore, we discuss current therapies under study and the development of vaccines to prevent this disease.
登录
查看更多内容
影响因子：
13.6
作者：
通讯作者：
--
DOI：
10.1016/j.dsx.2020.04.020
发表时间：
2020-07-01
影响因子：
10
作者：
Astuti, Indwiani;Ysrafil
通讯作者：
Ysrafil
影响因子：
7.6
作者：
Báez-Santos YM;St John SE;Mesecar AD
通讯作者：
Mesecar AD
DOI：
10.1093/infdis/jit609
发表时间：
2014-04-01
期刊：
The Journal of infectious diseases
影响因子：
--
作者：
Agnihothram S;Gopal R;Yount BL Jr;Donaldson EF;Menachery VD;Graham RL;Scobey TD;Gralinski LE;Denison MR;Zambon M;Baric RS
通讯作者：
Baric RS
影响因子：
56.9
作者：
Baum, Alina;Fulton, Benjamin O.;Kyratsous, Christos A.
通讯作者：
Kyratsous, Christos A.